← Back to Search

Anti-inflammatory Antibiotic

Minocycline for Stroke

Phase 2 & 3

Recruiting

Research Sponsored by Maimonides Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO (World Health Organization) guidelines

Acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed

Timeline

Screening 3 weeks

Treatment Varies

Follow Up on admission, at discharge (within 2 weeks), 30 days and at 90 days after discharge

Awards & highlights

Study Summary

This trial will investigate if Minocycline can improve outcomes for stroke patients beyond standard care.

Who is the study for?

This trial is for adults over 18 with recent (less than 24 hours) stroke symptoms or imaging showing a stroke, who can take oral medication. It's not for those allergic to Tetracycline drugs, pregnant women, patients with severe illnesses affecting life expectancy within a year, renal failure cases, or existing infections needing antibiotics.Check my eligibility

What is being tested?

The study tests if Minocycline taken orally (200mg daily for five days), starting within the first day of stroke symptoms along with standard care improves outcomes compared to standard care alone. Outcomes are measured using NIHSS and mRS scales at different times post-stroke.See study design

What are the potential side effects?

Minocycline may cause side effects like dizziness, fatigue, gastrointestinal issues such as nausea or diarrhea, skin reactions like rashes or itching and in rare cases may affect liver enzymes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I recently had symptoms or imaging results that show a stroke due to lack of blood flow.

Select...

I recently started having trouble with my brain functions due to bleeding inside my brain.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ on admission, at discharge (within 2 weeks), 30 days and at 90 days after discharge

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~on admission, at discharge (within 2 weeks), 30 days and at 90 days after discharge

This trial's timeline: 3 weeks for screening, Varies for treatment, and on admission, at discharge (within 2 weeks), 30 days and at 90 days after discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

NIHSS (National Institutes of Health Stroke Scale, range 1-42, with higher scores indicating greater severity ) and mRS (Modified Rankin Scale, 0-6, the higher the worse, 6 means dead) Scale)scores) on admission, discharge and on day 90 post-stroke

Secondary outcome measures

In-hospital and 30-day mortality

Intracranial hemorrhage in patients treated with intravenous alteplase or catheter-based therapies

Side effects data

From 2016 Phase 4 trial • 10 Patients • NCT02124811

40%

Inpatient psychiatric hospitalization

20%

Hospitalization due to ischemic colitis

20%

Hypotension

100%

80%

60%

40%

20%

Study treatment Arm

Low CRP

High CRP

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Standard Stroke Care with MinocyclineExperimental Treatment1 Intervention

560 patients in the Minocycline arm will receive Minocycline 200 mg every 24 hours for five days with standard stroke care

Group II: Standard Stroke Care without MinocyclineActive Control1 Intervention

560 Patients will receive standard stroke care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Minocycline

2005

Completed Phase 4

~1000

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Maimonides Medical CenterLead Sponsor

69 Previous Clinical Trials

14,175 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available openings for participants in this experiment?

"The information available on clinicaltrials.gov confirms that this particular medical trial has stopped recruiting participants as of October 25th, 2023. Despite the conclusion of this study, there are still over 1,200 other trials actively looking for new patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Maimonides Minocycline in Stroke Study

Qingliang T. Wang 2023. "Maimonides Minocycline in Stroke Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06107725.